GS7.DE Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Jul 2022 @ 17:35):

Stats
Tagesvolumen	290 930
Durchschnittsvolumen	0
Marktkapitalisierung	0.00
EPS	€0.230 ( 2022-06-29 )
Last Dividend	€0.163 ( 2022-08-18 )
Next Dividend	€0 ( N/A )
P/E	17.31
ATR14	€0 (0.00%)

GSK plc Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

GSK plc Finanzdaten

Annual	2021
Umsatz:	€34.11B
Bruttogewinn:	€22.51B (65.99 %)
EPS:	€1.102

FY	2021
Umsatz:	€34.11B
Bruttogewinn:	€22.51B (65.99 %)
EPS:	€1.102

FY	2020
Umsatz:	€34.10B
Bruttogewinn:	€22.40B (65.68 %)
EPS:	€1.426

FY	2019
Umsatz:	€33.75B
Bruttogewinn:	€21.89B (64.85 %)
EPS:	€1.158

Financial Reports:

No articles found.

GSK plc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0.163 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

GSK plc Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.49 - good (84.92%) | Divividend Growth Potential Score: 4.55 - Potential for dividend initiation, but uncertain (9.01%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.140	2004-02-18
Last Dividend	€0.163	2022-08-18
Next Dividend	€0	N/A
Payout Date	2022-10-06
Next Payout Date	N/A
# dividends	75	--
Total Paid Out	€12.75	--
Avg. Dividend % Per Year	0.00%	--
Score	4.21	--
Div. Sustainability Score	8.49
Div.Growth Potential Score	4.55
Div. Directional Score	6.52	--

Next Divdend (Est)
(2024-06-28)

€0 Estimate 0.00 %

Dividend Stability

0.19 Bad

Dividend Score

4.21

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
GRM.DE	Ex Dividend Knight	2023-07-07	Quarterly	0.00%
RHK.DE	Ex Dividend Junior	2023-06-09	Sporadic	0.00%
BMW.DE	Ex Dividend Junior	2023-05-12	Annually	0.00%
INS.DE	Ex Dividend Junior	2023-06-15	Annually	0.00%
SZG.DE	Ex Dividend Junior	2023-05-26	Annually	0.00%
CVS.DE	Ex Dividend Knight	2023-10-19	Quarterly	0.00%
LXS.DE	Ex Dividend Junior	2023-05-25	Annually	0.00%
2GB.DE	Ex Dividend Junior	2023-06-14	Annually	0.00%
VOS.DE	Ex Dividend Junior	2023-05-25	Sporadic	0.00%
ENI.F	Ex Dividend Knight	2023-11-20	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.149	1.500	7.01	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0644	1.200	7.85	9.42	[0 - 0.3]
returnOnEquityTTM	0.344	1.500	7.29	10.00	[0.1 - 1]
payoutRatioTTM	0.785	-1.000	2.15	-2.15	[0 - 1]
currentRatioTTM	0.789	0.800	-1.055	-0.844	[1 - 3]
quickRatioTTM	0.183	0.800	-3.63	-2.90	[0.8 - 2.5]
cashRatioTTM	0.181	1.500	-0.108	-0.162	[0.2 - 2]
debtRatioTTM	0.306	-1.500	4.91	-7.36	[0 - 0.6]
interestCoverageTTM	7.03	1.000	8.51	8.51	[3 - 30]
operatingCashFlowPerShareTTM	1.998	2.00	9.33	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.261	2.00	9.37	10.00	[0 - 20]
debtEquityRatioTTM	1.606	-1.500	3.58	-5.37	[0 - 2.5]
grossProfitMarginTTM	0.660	1.000	2.34	2.34	[0.2 - 0.8]
operatingProfitMarginTTM	0.162	1.000	8.77	8.77	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.329	1.000	9.28	9.28	[0.2 - 2]
assetTurnoverTTM	0.431	0.800	-0.458	-0.367	[0.5 - 2]
Total Score				8.49

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.76	1.000	8.71	0	[1 - 100]
returnOnEquityTTM	0.344	2.50	8.26	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.261	2.00	9.58	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.998	2.00	9.33	10.00	[0 - 30]
payoutRatioTTM	0.785	1.500	2.15	-2.15	[0 - 1]
pegRatioTTM	0.188	1.500	-2.08	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.233	1.000	6.67	0	[0.1 - 0.5]
Total Score				4.55

GSK plc

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.